Phaseline

Companies › Dragonboat Biopharmaceutical Company

Dragonboat Biopharmaceutical Company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BC006
Autoantibody inhibitor targeting AT1R and M3R
–Phase 2Idiopathic Pulmonary Fibrosis (IPF)Apr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07447102BC006Phase 2Idiopathic Pulmonary Fibrosis (IPF)RespiratoryApr 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Expedition Therapeutics Kinaset Therapeutics Melius Pharma Jianmin Pharmaceutical Group Endeavor Biomedicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.